Skip to main content Help with accessibility Skip to main navigation

Liothyronine

Indication

Liothyronine as monotherapy for the chronic management of hypothyroidism

Black

Brand:

Tertroxin

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

Prescribing within Primary Care — Black

Liothyronine is NOT recommended for use by the NHS in Lancashire and South Cumbria in the following setting:

as an add-on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxine:

There is insufficient evidence to demonstrate efficacy in the above setting, availability of the drug is limited, adverse events are more prevalent than for Levothyroxine monotherapy and there would be a considerable cost pressure to the health economy if prescribed for all patients with normal serum TSH levels and have persistent symptoms.

As monotherapy for the chronic management of hypothyroidism:

There is a paucity of evidence in the literature supporting the use of Liothyronine monotherapy for the management of hypothyroidism. Liothyronine is not licensed for the long-term management of hypothyroidism.

Recommendation

LSCMMG Recommendation:

Black

Reason for decision:

Not recommended for prescribing on the NHS in Lancashire & South Cumbria

Decisions of Lancashire local decision making groups

Black
Black
Black
Black
Black
Black
Black
Black
What do the colours mean?

Last Updated: 01 - Oct - 2019